Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 8/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12117438 | 0.81 | LMNA (0.63) | LMNAPKMCYP11B1CYP11B2CYP3A4 | |
| SCHEMBL31288142 | 0.77 | CYP3A4 (0.48) | LMNAPKMCYP11B1CYP11B2CYP3A4 | |
| SCHEMBL8418297 | 0.77 | LMNA (0.58) | LMNAPKMCYP11B1CYP11B2CYP3A4 | |
| SCHEMBL22170248 | 0.77 | LMNA (0.58) | LMNAPKMCYP11B1CYP11B2CYP3A4 | |
| SCHEMBL30292019 | 0.77 | LMNA (0.58) | LMNAPKMCYP11B1CYP11B2CYP3A4 | |
| SCHEMBL19036903 | 0.75 | LMNA (0.56) | LMNAPKMCYP11B1CYP11B2CYP3A4 | |
| SCHEMBL31288149 | 0.74 | LMNA (0.54) | LMNAPKMCYP11B1CYP11B2CYP3A4 | |
| SCHEMBL10066174 | 0.74 | LMNA (0.63) | LMNAPKMCYP11B1CYP11B2CYP3A4 | |
| SCHEMBL30298766 | 0.74 | AAK1 (0.70) | LMNAPKMCYP11B1CYP11B2NOTUM | |
| SCHEMBL22165625 | 0.74 | AAK1 (0.70) | LMNAPKMCYP11B1CYP11B2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169652-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. | 2022-06-02 | — | — | US | disclosed |
| US-11091492-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2021-08-17 | — | — | US | disclosed |
| US-20200385390-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2020-12-10 | — | — | US | disclosed |
| US-10570135-B2 | Substituted pyrazolo[1,5-A]pyrimidines and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20170334916-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334916-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PARK7, PNP, GAA | LMNA 1610/4885PKM 101/4885CYP11B1 2596/4885 |
| US-10570135-B2 | Substituted pyrazolo[1,5-A]pyrimidines and their use in the treatment of medical disorders | PARK7, PNP, GAA | LMNA 1610/4885PKM 101/4885CYP11B1 2596/4885 |
| US-20220169652-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PARK7, PNP, GAA | LMNA 1610/4885PKM 101/4885CYP11B1 2596/4885 |
| US-20200385390-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PARK7, PNP, GAA | LMNA 1610/4885PKM 101/4885CYP11B1 2596/4885 |
| US-11091492-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | PARK7, PNP, GAA | LMNA 1610/4885PKM 101/4885CYP11B1 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.